CRVS News

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more

• In a week shortened by Good Friday, there was one biotech pricing and one initial filing.
• The first quarter, marked by the least amount of IPO activity since the 1Q 2009, comes to a conclusion next week. Quarter to date,...read more

Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS....read more

Corvus Pharmaceuticals is the only IPO on the calendar during the shortened holiday week. Since reaching a year-to-date low on February 11, the S&P 500 has gained 12%, while the market cap-weighted Renaissance IPO Index has surged 19%. The VIX...read more